newsfilter
← Latest News
GlobeNewswire·

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent